Zhejiang Hisoar Pharmaceutical Co Ltd (002099) — Strategic Asset Allocation Index
Zhejiang Hisoar Pharmaceutical Co Ltd (002099) has a Strategic Asset Allocation Index of 50.3% as of September 2023. Strategic assets (PP&E of CN¥3.01 Billion plus long-term investments of CN¥-) total CN¥3.01 Billion, measured against net assets of CN¥5.98 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check 002099 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Zhejiang Hisoar Pharmaceutical Co Ltd Strategic Asset Allocation Index (2003–2022)
This chart shows how Zhejiang Hisoar Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 20 annual periods from 2003 to 2022. As of September 2023, the index stands at 50.3%, representing strategic assets of CN¥3.01 Billion against net assets of CN¥5.98 Billion CNY. See 002099 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Zhejiang Hisoar Pharmaceutical Co Ltd (2003–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Zhejiang Hisoar Pharmaceutical Co Ltd from 2003 to 2022, covering 20 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Zhejiang Hisoar Pharmaceutical Co Ltd (002099) market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 50.7% | CN¥3.10 Billion | CN¥3.10 Billion | CN¥- | CN¥6.10 Billion | ▲ +2.0 pp |
| 2021 | 48.8% | CN¥2.98 Billion | CN¥2.98 Billion | CN¥- | CN¥6.11 Billion | ▲ +5.0 pp |
| 2020 | 43.8% | CN¥2.56 Billion | CN¥2.56 Billion | CN¥- | CN¥5.85 Billion | ▲ +2.7 pp |
| 2019 | 41.1% | CN¥2.35 Billion | CN¥2.29 Billion | CN¥67.88 Million | CN¥5.72 Billion | ▲ +4.8 pp |
| 2018 | 36.3% | CN¥1.96 Billion | CN¥1.89 Billion | CN¥67.89 Million | CN¥5.39 Billion | ▲ +6.0 pp |
| 2017 | 30.3% | CN¥1.56 Billion | CN¥1.48 Billion | CN¥81.09 Million | CN¥5.14 Billion | ▼ -1.4 pp |
| 2016 | 31.7% | CN¥1.51 Billion | CN¥1.31 Billion | CN¥201.05 Million | CN¥4.77 Billion | ▼ -12.0 pp |
| 2015 | 43.7% | CN¥1.56 Billion | CN¥1.54 Billion | CN¥24.31 Million | CN¥3.57 Billion | ▼ -2.7 pp |
| 2014 | 46.4% | CN¥1.47 Billion | CN¥1.47 Billion | CN¥- | CN¥3.18 Billion | ▼ -137.9 pp |
| 2013 | 184.2% | CN¥1.17 Billion | CN¥1.17 Billion | CN¥- | CN¥632.80 Million | ▲ +52.7 pp |
| 2012 | 131.5% | CN¥970.47 Million | CN¥970.47 Million | CN¥- | CN¥738.05 Million | ▲ +54.8 pp |
| 2011 | 76.7% | CN¥565.30 Million | CN¥565.30 Million | CN¥- | CN¥736.96 Million | ▲ +1.7 pp |
| 2010 | 75.0% | CN¥478.59 Million | CN¥478.59 Million | CN¥- | CN¥638.04 Million | ▲ +0.1 pp |
| 2009 | 74.9% | CN¥420.98 Million | CN¥420.98 Million | CN¥- | CN¥561.79 Million | ▼ -2.1 pp |
| 2008 | 77.1% | CN¥422.01 Million | CN¥422.01 Million | CN¥- | CN¥547.50 Million | ▲ +11.8 pp |
| 2007 | 65.3% | CN¥351.43 Million | CN¥351.43 Million | CN¥- | CN¥538.06 Million | ▲ +3.9 pp |
| 2006 | 61.4% | CN¥318.93 Million | CN¥318.93 Million | CN¥- | CN¥519.27 Million | ▼ -36.7 pp |
| 2005 | 98.1% | CN¥179.50 Million | CN¥179.50 Million | CN¥- | CN¥182.96 Million | ▼ -3.8 pp |
| 2004 | 101.9% | CN¥134.51 Million | CN¥134.51 Million | CN¥- | CN¥132.03 Million | ▼ -37.3 pp |
| 2003 | 139.2% | CN¥118.34 Million | CN¥118.34 Million | CN¥- | CN¥85.03 Million | — |